Repair Impact Fund
VC Fund
Hellerup, Denmark
Repair Impact Fund is a VC fund in Hellerup focused on Biotechnology and Health Care. Novo Holdings established the REPAIR Impact Fund commissioned by the Novo Nordisk Foundation in February 2018 to invest in companies involved in discovering and the early-stage development of therapies targeting resistant microorganisms.REPAIR is an acronym: Replenishing and Enabling the Pipeline for Anti-Infective Resistance.The Novo NordiskFoundation is commissioning the initiative, and Novo Holdings is executing it.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Repair Impact Fund invests in
Stages Repair Impact Fund invests in
Countries Repair Impact Fund invests in
Investment Focus
Industry
- Biotechnology 7 (58%)
- Health Care 3 (25%)
- Therapeutics 2 (17%)
- Pharmaceutical 2 (17%)
- Medical 1 (8%)
Stage
- Funding Round 4 (33%)
- Series A 2 (17%)
- Series B 2 (17%)
- Grant 1 (8%)
- Series C 1 (8%)
Country
- United States 2 (17%)
- France 1 (8%)
- Denmark 1 (8%)
- Switzerland 1 (8%)
- United Kingdom 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
LimmaTech Biologics
|
LimmaTech Biologics AG is a clinical-stage biopharmaceutical company. | $3M / Series A / Feb 01, 2024 | |
Revagenix
|
Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs. | Series B / Jan 05, 2024 | |
|
Revagenix
|
Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs. | Series B / Jan 05, 2024 | |
|
LimmaTech Biologics
|
LimmaTech Biologics AG is a clinical-stage biopharmaceutical company. | $36.5M / Series A / Oct 09, 2023 | |
Minervax
|
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M / Series C / Dec 15, 2022 | |
|
Minervax
|
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $52M / Series B / Dec 15, 2020 | |
|
Revagenix
|
Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs. | $4M / Series A / Jan 01, 2020 | |
Procarta Biosystems
|
Procarta Biosystems Ltd., established in 2007 by the scientific founders, Dr. Michael McArthur and Professor Mervyn Bibb, is a spin-out company from the John Innes Centre, Norwich, a world renowned scientific centre of excellence in plant science and microbiology. The company was initially established through Plant Bioscience Ltd (PBL), theinternationally regarded group specialising in early stage technology investment and IP management, on behalf of the JIC, the Sainsbury Laboratory and the Biotechnology and Biological Sciences Research Council.Procarta received seed funding in 2008 from the Rainbow and Iceni Seedcorn Funds and is currently headquartered on the Norwich Research Park. | $1.6M / Mar 05, 2019 | |
|
Minervax
|
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $4.8M / Grant / Jan 21, 2019 | |
|
IBT Vaccines
|
IBT Vaccines is a biotechnology company. | $3.9M | |
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Repair Impact Fund invest in?
Repair Impact Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Funding Round and Series A stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Repair Impact Fund last invest?
The most recent investment recorded for Repair Impact Fund closed in Feb 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
